Abstract
1. The 1,4-dihydropyridine nucleus serves as the scaffold for important cardiovascular drugs—calcium antagonists—including nifedipine, nitrendipine, amlodipine, and nisoldipine, which exert their antihypertensive and antianginal actions through actions at voltage-gated calcium channels of the CaV1 (L-type) class.
2. These drugs act at a specific receptor site for which defined structure-activity relationships exist, including stereoselectivity.
3. Despite the widespread occurrence of the CaV1 class of channel, the calcium antagonists exhibit significant selectivity of action in the cardiovascular system. This selectivity arises from a number of factors including subtype of channel, state-dependent interactions, pharmacokinetics, and mode of calcium mobilization.
4. The 1,4-dihydropyridine nucleus is also a privileged structure or scaffold that can, when appropriately decorated substituents, interact at diverse receptors and ion channels, including potassium and sodium channels and receptors of the G-protein class.
Similar content being viewed by others
References
Agrawal, V. K., Tang, S. B., Wolowyk, M. W., and Knaus, E. E. (1990). Synthesis and activity of 1,4-dihydropyridine analogues of histamine H2-receptor antagonists. Drug Design Deliv. 6:101–109.
Anrep, G. V., Kenawy, M. R., and Barsoum, G. S. (1949). The coronary vasodilator action of khellin. Am. Heart. J. 37:531–542.
Bossert, F., and Vater, W. (1989). 1,4-Dihydropyridines—a basis for developing new drugs. Med. Res. Rev. 9:291–324.
Catterall, W. A. (2000). Structure and function of voltage-gated calcium channels. Annu. Rev. Biochem. 65:493–531.
Catterall, W. A., Chandy, K. G., and Gutman, G. A. (2002). The IUPHAR Compendium of Voltage-Gated Ion Channels. IUPHAR Media, Leeds, United Kingdom.
Chin, M. H., Cioffi, C. L., Garay, M., Neale, R. F., Shetty, S. S., Del Grande, D., Mugrage, B., Sills, M. A., and Lipson, K. E. (1996). The unusual binding properties of the endothelin receptor antagonuit CGS 27830 distinguishes receptor/agonist interactions. J. Pharmacol. Exp. Ther. 276:74–83.
Cooper, K., Fray, M. J., Parry, M. J., Richardson, K., and Steele, J. (1992). 1,4-Dihydropyridines as antagonists of platelet activating factor 1. Syntheses and structure-activity relationships of 2-(4-heterocyclyl) phenyl derivatives. J. Med. Chem. 35:3115–3129.
Daly, J. W. (1998). Thirty years of discovering arthropod alkaloids in amphibian skin. J. Nat. Prod. 61: 162–172.
Drocourt, L., Pascussi, J.-M., Asenat, E., Fabre, J.-M., Maurel, P., and Vilarem, M.-J. (2001). Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab. Dispos. 29:1325–1331.
Elvelin, L. and Elmfeldt, D. (1989). Felodipine: A review of its pharmacological and clinical properties. Drugs Today 25:589–596.
Epstein, M. (Ed.) (2002). Calcium Antagonists in Clinical Medicine. Hanley and Belfus, Philadelphia, PA.
Evans, B. E., Rittle, K. E., Bock, M. G., DiPardo, R. M. et al. (1988). Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31:2235–2246.
Fleckenstein, A. (1983). Calcium Antagonism in Heart and Smooth Muscle. Wiley, New York.
Frank, C. A., Forst, J. M., Harris, R. J., Kau, S. T., Li, J. H., Ohmmachb, C.-J., Smith, R. W., Trainor, D. A., and Trivedi, S. (1993). Dihydropyridine KATP potassium channel openers. Bioorg. Med. Chem. Lett. 3:2725–2726.
Godfraind, T., Salomone, S., Dessy, C., Verhelst, B., Dion, R., and Schoemerts, J. C. (1992). Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J. Cardiovasc. Pharmacol. 20(Suppl. 5): S34-S41.
Goldmann, S., and Stoltefuss, J. (1991). 1,4-Dihydropyridines: Effects of chirality and conformation on the calcium antagonist and agonist activities. Angew. Chem. Int. Ed. 30: 1559–1578.
Hamaguchi, N., True, T. A., Saussy, D. L., and Jeffs, P. W. (1996). Phenylalanine in the second membrane-spanning domain of α1a-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry 35:14312–14317.
Hockerman, G. H., Peterson, B. Z., Johnson, B. D., and Catterall, W. A. (1997). Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. 37:361–396.
Hu, H., and Marban, E. (1998). Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties. Mol. Pharmacol. 53: 902–907.
Ito, H., Klugbauer, H., and Hofmann, F. (1997). Transfer of the high affinity dihydropyridine sensitivity from L-type to non-L-type calcium channel. Mol. Pharmacol. 52:735–740.
Jiang, J.-L., Li, A.-H., Jang, S.-Y., Chang, L., Melman, N., Moro, S., Ji, X.-D., Lobkovsky, M. B., Clardy, J. C., and Jacobson, K. A. (1999). Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl-1,4-dihydropyridines as selective A3 adenosine receptor antagonists. J. Med. Chem. 42:3055–3065.
Jiang, J.-L., van Rhee, A. M., Chang, L., Patchornik, A., Ji, X.-D., Evans, P., Melman, N., and Jacobson, K. A. (1997). Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. J. Med. Chem. 40:2596–2608.
Jiang, J.-L., van Rhee, A. M., Melman, N., Ji, X.-D., and Jacobson, K. A. (1996). 6-Phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J. Med. Chem. 39:4667–4675.
Kwon, Y. W., and Triggle, D. J. (1991). Effects of Ca2+ channel ligands on [3H]QNB binding at m1 and m3 muscarinic receptors. Biochem. Pharmacol. 22:267–270.
Lacinova, L., Klugbauer, N., and Hofmann, F. (2000). State-and isoform-dependent interaction of isradipine with the α1C L-type calcium channel. Pflug. Arch. 440:50–60.
Lavilla, R. (2002). Recent developments in the chemistry of dihydropyridines. J. Chem. Soc., Perkin Trans. 1:1141–1156.
Li, J. H. (2002). Phaarmacology of ZM244085: A novel bladder-selective dihydropyridine KATP channel activator. Cardiovasc. Drug Rev. 15:220–231.
Lopez, M. G., Fonteriz, R. I., Gandia, L., de la Fuente, M., Villarroya, M., Garcia-Sancho, J., and Garcia, A. G. (1993). The nicotinic acetylcholine receptor of the bovine chromaffin cell, a new target for 1,4-dihydropyridines. Eur. J. Pharmacol. 247:199–207.
Malstrom, R. E., Balmer, K. C., Weilitz, J., Nordlander, M., and Sjolander, M. (2001). Pharmacology of H 394/84, a dihydropyridine neuropeptide Y Y1 receptor antagonist in vivo. Eur. J. Pharmacol. 418:95–104.
Mann, J. (1992). Murder Magic and Medicine. Oxford University Press, Oxford.
Mayeux, P. R., Mais, D. E., and Halushka, P. V. (1991). Interactions of dihydropyridine Ca2+ channel agonists with the human thromoboxane A2/Prostaglandin H2 receptor. Eur. J. Pharmacol. 206:15–21, 1996.
Morel, N., Buryi, V., Feron, O., Gomez, J.-P., Christen, M. O., and Godfraind, T. (1998). The action of calcium channel blockers on recombinant L-type calcium channel α1 subunits. Br. J. Pharmacol. 125:1005–1012.
Nagarathnam, D., Wetzel, J. M., Miao, S. W., Marzbadi, M. R., Chiu, G., Wong, W. C., Hong, X., Fang, J., Forray, C., Branchek, T. A., Heydorn, W. A., Chang, R. S. L., Broten, T., Schorn, T. W., and Gluchowski, C. (1998). Design and synthesis of novel a1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia. J. Med. Chem. 41:5320–5333.
Nelson, D. M., and Cox, M. M. (2000). Lehninger: Principles of Biochemistry. Worth Publishers, New York.
Olivera, B. M. (1999). Speciation of cone smails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns. Ann. N.Y. Acad. Sci. 870:223–237.
Patchett, A. A., and Nargund, R. P. (2000). Privileged structures—An update. Ann. Rep. Med. Chem. 35:289–298.
Pointdexter, G. S., Bruce, M. A., LeBoulluec, K. L., Monkouic, I., Martin, S. W., Parker, E. M., Iben, L. G., McGovern, R. T., Ortiz, A. A., Stanley, J. A., Mattson, G. K., Kozlowski, M., Arcuri, M., and Antal-Zimanyi, I. (2002). Dihydropyridine neuropeptide Y Y1 receptor antagonists. Biorg. Med. Chem. Lett. 12:379–382.
Schreiber, S. (2000). Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287: 1964–1969.
Shen, G. S., Layer, R. T., and McCabe, R. T. (2000). Conopeptides: From deadly venoms to novel therapeutics. Drug Discovery Today 5:98–106.
Shibasaki, K., Uchida, W., Takizawa, K., Masuda, N., Okazaki, T., Inagaki, O., Asano, M., and Takenaka, T. (1997). Cardiovascular effects of YM 430,a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol. Pharm. Bull. 20:230–236.
Sinneger, M. J., Wang, Z., Grabner, M., Hering, S., Striessnig, J., Glossman, H., and Mitterdoerfer, J. (1997). Nine L-type amino acid residues confer full 1,4-dihydropyridine sensitivity to the neuronal calcium channel α1a subunit: Role of L-type Met1188. J. Biol. Chem. 272:27686–27693.
Skeen, G. A., Twyman, R. E., and White, H. S. (1993). The dihydropyridine nitrendipine modulates N-methyl-D-aspartate receptor channel function in mammalian neurons. Mol. Pharmacol. 44:443–450.
Skeen, G. A., White, H. S., and Twyman, R. E. (1994). The dihydropyridine nitrendipine reduces N-methyl-D-aspartate (NMDA)-evoked currents of rodent cortical neurons through a direct interaction with the NMDA receptor-associated ion channel. J. Pharmacol. Exp. Ther. 271:30–38.
Striessnig, J., Grabner, M., Mitterdorfer, J., Hering, S., Sinneger, M. J., and Glossman, H. (1998). Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol. Sci. 19:108–115.
Sunkel, C. E., de Casa-Juana, M. D. de, Cillero, F. J., Priego, J. G., and Ortega, M. P. (1988). Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines. J. Med. Chem. 31:1886–1890.
Sunkel, C. E., Casa-Juana, M. F. de, Santos, L., Gomez, M. M., Villarroya, M., Gonzalez-Morales, M. A., Priego, J. G., and Ortega, M. P. (1990). 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-Acether antagonists. J. Med. Chem. 33:3205–3210.
Triggle, D. J. (1990). Calcium antagonists. History and perspective. Stroke 21(Suppl. IV): IV49-IV58.
Triggle, D. J. (2002). Mechanisms of action of calcium antagonists. In Epstein, M. (ed.), Calcium Antagonists in Clinical Medicine, Hanley and Belfus, Philadelphia, pp. 1–32.
Triggle, D. J. (2003a). The 1,4-dihydropyridine nucleus: A pharmacophoric template. MiniRev. Med. Chem. 3:166–175.
Triggle, D. J. (2003b). 1,4-Dihydropyridine calcium channel ligands: Selectivity of action. Drug Discovery Research. 58: 5–17.
Triggle, D. J., Langs, D. A., and Janis, R. A. (1989). Ca2+ channel ligands: Structure-function relationships of the 1,4-dihydropyridines. Med. Res. Rev. 9:123–180.
Trivedi, S., Potter-Lee, L., McConville, M. W., Li, J. H., Ohnmacht, C. J., Trainor, D. A., and Kau, S. T. (1995). K-Channel opening activity of dihydropyridine ZM244085: Effect on 86Rb efflux and [3H]-P1075 binding in urinary tract smooth muscle. Res. Commun. Mol. Path. Pharmacol. 88:137–155.
van Rhee, A. M., Jiang, J.-L., Melman, N., Olah, M. E., Stiles, G. L., and Jacobson, K. A. (1996). Interaction of 1,4-dihydropyridines and pyridine derivatives with adenosine receptors; selectivity for A3 receptors. J. Med. Chem. 39:2980–2989.
Welling, A., Kwan, Y. K., Bosse, E., Flockerzi, V., Hofmann, F., and Kass, R. S. (1993). Subunit-dependent modulation of recombinant L-type calcium channels. Circ. Res. 73:974–980.
Wess, G., Urmann, M., and Sickenerger, B. (2001). Medicinal chemistry: Challenges and opportunities. Angew. Chem. 40:3341–3350.
Wiley, R. A., and Rich, D. H. (1993). Peptidomimetics derived form natural products. Med. Res. Rev. 13:327–384.
Wong, W. C., Chiu, G., Wetzel, J. M., Marzabadi, M. R., Nagarathnam, D. Wang, D., Fang, J., Mko, S. W., Hong, X., Forray, C., Vaysse, P. J.-J., Branchek, T. A., and Gluchowski, C. (1998). Identification of a dihydropyridine as potent α1a adrenoceptor-selective antagonist that inhibits phenylephrine-induced contraction of the human prostate. J. Med.Chem. 41:2643–2650.
Zuhlke, R. D., Bouron, A., Soldatov, N. M., and Reuter, H. (1998). Ca2+ channel sensitivity towards the blocker isradipine is affected by the alternative splicing of the human α1c subunit gene. FEBS Lett. 427:220–234.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Triggle, D.J. 1,4-Dihydropyridines as Calcium Channel Ligands and Privileged Structures. Cell Mol Neurobiol 23, 293–303 (2003). https://doi.org/10.1023/A:1023632419813
Issue Date:
DOI: https://doi.org/10.1023/A:1023632419813